1-12 of 12
Hongfang Wang, PhD
Close
Sort by
Journal Articles

Longitudinal Molecular Profiling in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib

Sung Choe, PhD, Hongfang Wang, PhD, Gail J. Roboz, MD, Courtney D. DiNardo, MD MSCE, Eytan M. Stein, MD, Alice S. Mims, MD, Gabrielle T. Prince, MD, Justin M. Watts, MD, Bin Fan, PhD, Parham Nejad, BSc, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD, Richard M. Stone, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-136589
Published: 2020
Journal Articles

Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses

Hongfang Wang, PhD, Sung Choe, PhD, Courtney D. DiNardo, MD MSc, Eytan M. Stein, MD, Stéphane de Botton, MD PhD, Amir T. Fathi, MD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Lynn Quek, MD PhD, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 541.
https://doi.org/10.1182/blood-2019-122703
Published: 2019
Journal Articles

Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia

Sung Choe, PhD, Hongfang Wang, PhD, Courtney D. DiNardo, MD MSc, Eytan M. Stein, MD, Stephane De Botton, Amir T. Fathi, MD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Lynn Quek, MD PhD, Zenon Konteatis, PhD, Lenny Dang, PhD, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 545.
https://doi.org/10.1182/blood-2019-122671
Published: 2019
Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

James M. Foran, MD, Courtney D. DiNardo, MDMSc, Justin M. Watts, MD, Eytan M. Stein, MD, Stephane De Botton, Amir T. Fathi, MD, Gabrielle T. Prince, MD, Anthony Stein, MD, Richard M. Stone, MD, Prapti A. Patel, MD, Martin S. Tallman, MD, Sung Choe, PhD, Hongfang Wang, PhD, Vickie Zhang, PhD, Bin Fan, PhD, Katharine E. Yen, PhD, Abdulafeez Oluyadi, PharmD, Thomas Winkler, MD, Denice Hickman, BSN, Samuel V. Agresta, MD, Hua Liu, PhD, Bin Wu, PhD, Eyal C. Attar, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4254.
https://doi.org/10.1182/blood-2019-123946
Published: 2019
Journal Articles

Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy

Emily F Mason, MD PhD, Olga Pozdnyakova, MD PhD, Mikhail Roshal, MD PhD, Amir T. Fathi, MD, Eytan M. Stein, MD, Aaron C. Shaver, MD PhD, Mark G. Frattini, MD, Hongfang Wang, PhD, Lei Hua, PhD, Jimmy Mu, Caroline Almon, MS, Michael Cooper, MD, Richard M. Stone, MD, Robert P. Hasserjian, MD, Michael R. Savona, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1442.
https://doi.org/10.1182/blood-2019-123845
Published: 2019
Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

Courtney D. DiNardo, MDMSc, Justin M. Watts, MD, Eytan M. Stein, MD, Stephane de Botton, MD PhD, Amir T. Fathi, MD, Gabrielle T. Prince, MD, Anthony S. Stein, MD, James M. Foran, MD, Richard M. Stone, MD, Prapti A. Patel, MD, Martin S. Tallman, MD, Sung Choe, PhD, Hongfang Wang, PhD, Vickie Zhang, PhD, David Dai, PhD, Bin Fan, PhD, Katharine E. Yen, PhD, Stephanie M. Kapsalis, OTR, Denice Hickman, RN, Samuel V. Agresta, MD, Hua Liu, PhD, Bin Wu, PhD, Eyal C. Attar, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1812.
https://doi.org/10.1182/blood-2018-99-111264
Published: 2018
Journal Articles

Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions

Eytan M. Stein, MD, Courtney D. DiNardo, MDMSc, Amir T. Fathi, MD, Alice S. Mims, MD, Keith W. Pratz, MD, Michael R. Savona, MD, Anthony S. Stein, MD, Richard M. Stone, MD, Eric S. Winer, MD, Christopher S. Seet, MD, Hartmut Döhner, MD, Daniel A Pollyea, MD, James K McCloskey, MD, Olatoyosi Odenike, MD, Bob Lowenberg, MD, Gert J. Ossenkoppele, MD PhD, Prapti A. Patel, MD, Mikhail Roshal, MD PhD, Frederik Lersch, RN, Salah Nabhan, MS, Sung Choe, PhD, Hongfang Wang, PhD, Lei Hua, PhD, Caroline Almon, MS, Michael Cooper, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 560.
https://doi.org/10.1182/blood-2018-99-110449
Published: 2018
Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Gail J. Roboz, MD, Courtney D. DiNardo, MDMSc, Eytan M. Stein, MD, Stephane de Botton, MD PhD, Alice S. Mims, MD, Gabrielle T. Prince, MD, Jessica K. Altman, MD, Martha L. Arellano, MD, William B. Donnellan, MD, Harry P. Erba, MD PhD, Gabriel N. Mannis, MD, Daniel A Pollyea, MD, Anthony S. Stein, MD, Geoffrey L. Uy, MD, Justin M. Watts, MD, Amir T. Fathi, MD, Hagop M. Kantarjian, MD, Martin S. Tallman, MD, Sung Choe, PhD, David Dai, PhD, Bin Fan, PhD, Hongfang Wang, PhD, Vickie Zhang, PhD, Katharine E. Yen, PhD, Stephanie M. Kapsalis, OTR, Denice Hickman, RN, Hua Liu, PhD, Samuel V. Agresta, MD, Bin Wu, PhD, Eyal C. Attar, MD, Richard M. Stone, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 561.
https://doi.org/10.1182/blood-2018-99-110595
Published: 2018
Journal Articles

Genetic Profiling and Deep IDH1 Mutation Clearance to ≤0.04% in Ivosidenib (AG-120)-Treated Patients with Mutant IDH1 Relapsed or Refractory and Untreated AML

Richard M. Stone, MD, Sung Choe, PhD, Vickie Zhang, PhD, Benoit Marteyn, PhD, Virginie Penard-Lacronique, PhD, Hongfang Wang, PhD, Courtney D. DiNardo, MDMSc, Eytan M. Stein, MD, Amir T. Fathi, MD MD BS, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Eyal C. Attar, MD, Bin Wu, Stephane de Botton, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2684.
https://doi.org/10.1182/blood.V130.Suppl_1.2684.2684
Published: 2017
Journal Articles

Alternative Super-Enhancer States Determine MYC Sensitivity to Notch and Brd4 Inhibitors in T Lymphoblastic Leukemia/Lymphoma

Hongfang Wang, PhD, Yumi Yashiro-Ohtani, PhD, Chongzhi Zang, PhD, Yinling Joey Wong, MS, Will Bailis, PhD, Birgit Knoechel, MD PhD, Bradley Bernstein, MD PhD, Steve Blacklow, MD PhD, X. Shirley Liu, PhD, Warren S. Pear, MD PhD, Jon C Aster, MD PhD
Journal: Blood
Blood (2014) 124 (21): 863.
https://doi.org/10.1182/blood.V124.21.863.863
Published: 2014
Journal Articles

Genome-Wide Analysis of NOTCH1, ETS Family Factors, and RUNX1 Binding in Human T Lymphoblastic Leukemia Cells Reveals Distinct Regulatory Elements

Hongfang Wang, PhD, Chongzhi Zang, Ph.D, Len Taing, Hoifung Wong, Yumi Yashiro-Ohtani, Ph.D., Stephen Blacklow, MD. PhD., Warren S. Pear, MD, PhD, X. Shirley Liu, Ph.D, Jon C Aster, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1277.
https://doi.org/10.1182/blood.V120.21.1277.1277
Published: 2012
Journal Articles

Collaboration Between RUNX and NOTCH Pathways in T-Cell Acute Lymphoblastic Leukemia

Christopher R Jenkins, Hongfang Wang, PhD, Olena O Shevchuk, Sonya H Lam, Vincenzo Giambra, PhD, Louis Wang, Samuel D Gusscott, Jon C Aster, MD, PhD, Andrew P Weng, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1279.
https://doi.org/10.1182/blood.V120.21.1279.1279
Published: 2012